Ribociclib Adds Over One Year of Survival in Advanced Breast Cancer

MONALEESA-2 Final Analysis: First-line CDK4/6 inhibition demonstrates significant overall survival benefit (63.9 vs 51.4 months) despite high crossover in the control arm.

Design Phase 3 Randomized Controlled Trial Population Postmenopausal women with HR+, HER2- advanced breast cancer N 668 Duration Median follow-up 80 months Comparator Placebo + Letrozole Year 2022

Key Performance Indicators

PRIMARY

Hazard Ratio (Death)

0.76

95% CI: 0.63–0.93

24% reduction in risk of death

PRIMARY

Median OS Gain

+12.5

Months

Clinically meaningful extension

Statistical Significance

0.008

Two-sided P value

Highly significant

01

Survival benefit widens over time, reaching a 12% absolute difference at 6 years

Kaplan-Meier estimates of overall survival rates at 4, 5, and 6 years show a diverging benefit for the Ribociclib arm.

02

Ribociclib extends median life expectancy by more than a year

Comparison of Median Overall Survival (mOS) between the two treatment arms.

03

Survival advantage is consistent across key prognostic subgroups

Hazard Ratios for death across stratification factors. All point estimates favor Ribociclib (<1.0).

04

Treatment significantly delays the need for cytotoxic chemotherapy

Ribociclib delays the time to first subsequent chemotherapy by nearly 12 months compared to placebo.

05

Neutropenia is the primary high-grade safety signal

Incidence of Grade 3 or 4 Adverse Events of special interest. Neutropenia is common but manageable; other severe events are rare.

06

Survival win occurred despite higher post-progression CDK4/6 use in control arm

Percentage of patients receiving subsequent CDK4/6 inhibitors after discontinuing the trial regimen. The placebo group had higher access to these drugs later, yet Ribociclib upfront still showed superior OS.

Editorial Conclusion

“Ribociclib plus letrozole establishes a new benchmark for first-line treatment in HR+/HER2- advanced breast cancer, offering a median overall survival exceeding 5 years.”

24% relative reduction in risk of death compared to placebo.

Consistent benefit across subgroups, including older patients and those with visceral metastases.

Significant delay in time to subsequent chemotherapy, preserving quality of life.

Clinical Implication

These results support the use of Ribociclib + Letrozole as the standard of care for first-line therapy in this population.

Reference Data Sources & Abbreviations

Abbreviations

Abbrev	Meaning
OS	Overall Survival
HR	Hazard Ratio
CI	Confidence Interval
CDK4/6	Cyclin-dependent kinases 4 and 6

Source

N Engl J Med 2022;386:942-50

DOI: 10.1056/NEJMoa2114663

Limitations

Underrepresentation of Black patients (2.5%)
Wide confidence intervals in smaller subgroups